The Beatrice Hunter Cancer Research Institute logo
  • Dr. Gilles A. Robichaud, PhD


Assistant Professor, Université de Moncton, Department of Chemistry and Biochemistry; Adjunct Professor, Université de Sherbrooke, Department of Biochemistry; Adjunct Scientist at the Atlantic Cancer Research Institute; Board of Directors Canadian Cancer Society-NB Division


Assistant Professor, Université de Moncton

Research Interests:

Cancer cell signaling, oncogenes, breast cancer, gene regulation, tumor microenvironment, metastasis

Role of Oncogenes in the Development, Maintenance and Progression of Tumour Cells

One of our main research focus is the study of specific genes (oncogenes) and their signaling cascades in the transformation of healthy cells into their cancerous counterpart.  More specifically we are studying the molecular networks promoting cancer processes in human lymphocytic cells (lymphoma) and mammary epithelial cells (breast carcinoma). This research program will increase the understanding of cancer biology in order to develop more effective diagnostic tools and therapies against these diseases.

Involvement with BHCRI to date:

Dr. Robichaud is a BHCRI Senior Scientist, a member of the BHCRI Certificate Committee and a supervisor for CRTP trainees.


(506) 858-4320




Université de Moncton, Faculty of Sciences, room A-212, Moncton, New Brunswick, Canada, E1A 3E9


Nicolas Crapoulet, Pierre O’Brien, Rodney Ouellette and Gilles A. Robichaud, Coordinated expression of Pax-5 and FAK1 in metastasis.  In press: Anti-Cancer Agents in Medicinal Chemistry, 2011; 11, 643-649

Pierre O’Brien, Pier Morin, Rodney Ouellette and Gilles A. Robichaud, The Pax-5 gene : A pluripotent regulator of B cell differentiation and cancer disease.  In press: Cancer Research, September 2011

Jérémie Doiron; Al Haliffa Soultan ; Ryan Richard; Mamadou M Touré; Nadia Picot; Rémi Richard; Miroslava Čuperlović-Culf; Gilles A Robichaud; Mohamed Touaibia,. Synthesis and structure-activity relationship of 1- and 2-substituted-1,2,3-triazole letrozole-based analogues as aromatase inhibitors. European Journal of Medicinal Chemistry, 2011; 46, 4010-4024

Luc H. Boudreau, Nadia Picot, Jérémie Doiron, Benoît Villebonnet, Marc E. Surette, Gilles A. Robichaud and Mohamed Touaibia, Caffeoyl and cinnamoyl clusters with anti-inflammatory and anti-cancer effects. Synthesis and structure-activity relationship, New J. Chem., 2009; 33, 1932-1940

Gilles. A. Robichaud, Jean-Pierre Perreault and Rodney Ouellette.  Development of an isoform-specific gene suppression system: the study of the human Pax-5B transcriptional element. Nucleic Acid Research, 2008; 36(14):4609-4620

Asif Mufti*, Michel Lévesque*, Gilles A. Robichaud*, and J-P. Perreault. Development of ribozyme-based gene-inactivations; the example of the hepatitis delta virus ribozyme. Current Gene Therapy. 2007 June; 7(3):205-216.

Mark Laflamme* and Gilles A. Robichaud* Gene suppression technologies in high-throughput analysis: front- and back-side applications. OMICS. 2007; 11(2):129-142.

Gilles A. Robichaud, Michel Nardini, Mark Laflamme, Mira Cuperlovic-Culf, Rodney J. Ouellette. Human Pax-5 C-terminal isoforms possess distinct transactivation properties and are differentially modulated in normal and malignant B cells. Journal of Biological Chemistry; 2004, 279(48):49956-49963

Mira Culf, Gilles A. Robichaud, Michel Nardini and Rodney Ouellette.  Investigation of interaction between Pax-5 isoforms and thioredoxin using de novo modeling methods. In Silico Biology; 2003, 3(38):453-469.

* equally contributed to this work

Site by: Spectacle Group